WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera’s management team will host … [Read more…]

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants … [Read more…]

Walgreens COVID-19 Pulse Check finds Seniors are Less Socially Active Now than Before the Pandemic and Seeking Confidence in Socializing DEERFIELD, Ill.–(BUSINESS WIRE)–Today Walgreens unveils The Walgreens COVID-19 Pulse Check1, a quantitative study commissioned by the healthcare retailer, which surveyed over 1,000 senior adults 55 and older in the U.S. about their feelings on socializing … [Read more…]

Company-Sponsored Educational Events will Focus on Dry Eye Disease and IC-8® Apthera™ Intraocular Lens VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the … [Read more…]

Day 400 non-relapse mortality was 0% Previously reported data from the 14-week primary endpoint showed low rates of clinically significant viral infections and diseases in this high-risk patient population despite the expected high rates of viral reactivation Global Phase 3 pivotal posoleucel trials continue to progress with robust patient enrollment in the US, Europe and … [Read more…]

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible … [Read more…]

Financing Supports Advancement of an Industry-leading, Comprehensive Platform of RNA Technologies and a First-in-Class Portfolio of Programmable RNA Therapeutics Industry Veterans Niru Subramanian Appointed as Chief Operating Officer and Jonathan Piazza Appointed as Chief Financial Officer CAMBRIDGE, Mass.–(BUSINESS WIRE)–Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–#arrhythmias—Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr. Craig McPherson have joined Vektor’s advisory board. With more than two decades of … [Read more…]

BAAR, Switzerland–(BUSINESS WIRE)–#allergyimmunotherapy–Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation. The Stallergenes Greer Foundation, under the aegis of the Fondation de France, aims to build healthier futures for all by focusing on three key areas: Advancing … [Read more…]

– ILC’s Alfacyte product has potential to become a game-changing antiviral treatment in the ongoing global fight against Covid-19 MOTHERWELL, Glasgow–(BUSINESS WIRE)–Scottish biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for … [Read more…]